دورية أكاديمية
أعرض في EDS

Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.

التفاصيل البيبلوغرافية
العنوان: Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
المؤلفون: Gomez GG; Department of Pathology, University of Colorado Health Sciences Center, Denver, CO, USA., Kruse CA
المصدر: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2007 Apr; Vol. 30 (3), pp. 261-73.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9706083 Publication Model: Print Cited Medium: Print ISSN: 1524-9557 (Print) Linking ISSN: 15249557 NLM ISO Abbreviation: J Immunother Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Hagerstown, MD : Lippincott-Raven, c1997-
مواضيع طبية MeSH: Brain Neoplasms/*immunology , Glioma/*immunology , T-Lymphocytes, Cytotoxic/*immunology , Transforming Growth Factor beta/*metabolism, Antineoplastic Agents, Alkylating/pharmacology ; Apoptosis ; Calcium/metabolism ; Carmustine/pharmacology ; Cell Adhesion ; Cell Line, Tumor ; Coculture Techniques ; Cytokines/metabolism ; Extracellular Matrix/immunology ; Fas Ligand Protein/analysis ; Fas Ligand Protein/metabolism ; Gamma Rays ; HLA-A Antigens/analysis ; HLA-A Antigens/metabolism ; Humans ; Intercellular Adhesion Molecule-1/analysis ; Intercellular Adhesion Molecule-1/metabolism ; Killer Cells, Lymphokine-Activated/immunology ; Up-Regulation ; fas Receptor/analysis ; fas Receptor/metabolism
مستخلص: Two immunoresistant (IR) glioma cell variants, 13-06-IR29 and 13-06-IR30, were cloned from 13-06-MG glioma cell populations after receiving continuous immunoselective pressure from multiple alloreactive cytotoxic T lymphocyte (aCTL) preparations. Reapplication of aCTL immunoselective pressure to the IR clones, displaying a partial regain in sensitivity to aCTL after removal of the selective pressure, restored the resistance. The IR variants exhibited cross-resistance to non-human leukocyte antigen (HLA)-restricted effector cells and gamma-irradiation, but not to carmustine. The IR clones were characterized for factors that might contribute to the immunoresistance. The aCTL adhesion to extracellular matrix extracts derived from either the IR clones or the parental cells was similar and not impaired. Furthermore, aCTL binding to parental cells and IR clones was equal. Down-regulation of the cell recognition molecules, class I HLA or intercellular adhesion molecule-1 (ICAM-1), that would inhibit their recognition by aCTL was not observed on the IR clones. The down-regulation of Fas by the IR clones correlated with their resistance to FasL-induced apoptosis. HLA-G or FasL that might provide an immunotolerant environment or provide a means of counterattack to aCTL, respectively, were not associated with the IR phenotype. The aCTL, coincubated with the IR clones and parental cells, displayed up-regulation of multiple secreted cytokines. A significant up-regulation of bioactive transforming growth factor (TGF)-beta was observed in the IR clones compared with the parental cells. These data suggest that increased secretion of bioactive TGF-beta may inhibit aCTL lysis of the IR clones. Disruption of the TGF-beta signaling pathway may circumvent the resistance.
References: Hum Immunol. 1994 Sep;41(1):79-86. (PMID: 7836069)
Cancer Res. 2001 Apr 1;61(7):3084-91. (PMID: 11306491)
J Immunol. 2000 Oct 1;165(7):3663-72. (PMID: 11034370)
J Neuroimmunol. 1999 Dec;100(1-2):216-32. (PMID: 10695732)
Biotechnol Appl Biochem. 1997 Jun;25 ( Pt 3):197-205. (PMID: 9198273)
Neuro Oncol. 2005 Apr;7(2):122-33. (PMID: 15831231)
J Immunol. 2005 May 15;174(10):5950-8. (PMID: 15879087)
Cancer Cell. 2005 Nov;8(5):369-80. (PMID: 16286245)
J Immunol. 1993 Sep 15;151(6):2895-903. (PMID: 8376760)
Cancer. 1989 Oct 15;64(8):1629-37. (PMID: 2790675)
Hematol Oncol Clin North Am. 2001 Dec;15(6):1053-71. (PMID: 11770298)
J Neurosurg. 1993 Jun;78(6):944-51. (PMID: 8487077)
Cancer Res. 2004 Oct 15;64(20):7596-603. (PMID: 15492287)
J Immunol. 1994 Jun 1;152(11):5199-207. (PMID: 7514630)
J Neurooncol. 2002 Jan;56(1):13-9. (PMID: 11949822)
CA Cancer J Clin. 1998 Nov-Dec;48(6):331-60, 321. (PMID: 9838898)
J Neurooncol. 2003 Aug-Sep;64(1-2):63-9. (PMID: 12952287)
J Neurooncol. 1986;3(4):387-96. (PMID: 2420943)
Cancer Immunol Immunother. 2000 Mar;48(12):661-72. (PMID: 10752474)
Anticancer Res. 2001 Jul-Aug;21(4A):2561-7. (PMID: 11724322)
J Immunol. 1984 Dec;133(6):3387-95. (PMID: 6238097)
J Exp Med. 1987 Oct 1;166(4):991-8. (PMID: 3498791)
Clin Immunol. 2004 Jul;112(1):54-65. (PMID: 15207782)
Cancer. 1993 Jul 15;72(2):491-501. (PMID: 8319179)
Int J Cancer. 2000 May 20;89(3):251-8. (PMID: 10861501)
J Immunol. 2001 Jan 1;166(1):121-9. (PMID: 11123284)
Cancer Genet Cytogenet. 2006 Mar;165(2):121-34. (PMID: 16527606)
Immunity. 2000 Feb;12(2):171-81. (PMID: 10714683)
Hum Immunol. 2003 Nov;64(11):1064-72. (PMID: 14602237)
Neurosurgery. 1994 Apr;34(4):669-72; discussion 672-3. (PMID: 8008165)
Acta Neurochir (Wien). 1982;64(3-4):175-97. (PMID: 6215833)
Genomics. 1993 Feb;15(2):357-64. (PMID: 8095486)
Br J Exp Pathol. 1948 Feb;29(1):58-69. (PMID: 18865105)
J Immunol. 1999 Apr 15;162(8):4567-75. (PMID: 10201996)
Cancer Res. 1990 Oct 15;50(20):6683-8. (PMID: 2208133)
J Immunol. 2002 Jul 1;169(1):145-50. (PMID: 12077239)
Int J Cancer. 1996 Jul 17;67(2):275-82. (PMID: 8760599)
In Vitro Cell Dev Biol. 1992 Sep-Oct;28A(9-10):609-14. (PMID: 1331021)
Science. 1983 May 13;220(4598):739-42. (PMID: 6220469)
Cancer Res. 1992 Aug 15;52(16):4297-305. (PMID: 1643627)
Cancer Ther. 2005;3A:325-340. (PMID: 16467916)
J Immunol. 2000 Nov 1;165(9):4773-7. (PMID: 11045997)
Cancer Immunol Immunother. 2006 Jul;55(7):819-29. (PMID: 16187085)
Int J Cancer. 1989 May 15;43(5):880-5. (PMID: 2714894)
Cancer Immunol Immunother. 1997 Oct;45(2):77-87. (PMID: 9390198)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
J Interferon Cytokine Res. 2002 Dec;22(12):1209-16. (PMID: 12581494)
J Immunol. 1989 Nov 15;143(10):3222-9. (PMID: 2809198)
J Immunol. 1991 May 15;146(10):3289-97. (PMID: 1827481)
J Neuroimmunol. 2001 Nov 1;120(1-2):138-45. (PMID: 11694328)
J Reprod Immunol. 1999 Jul;43(2):203-11. (PMID: 10479056)
Cancer Res. 2000 Oct 15;60(20):5731-9. (PMID: 11059767)
Clin Immunol. 2002 Jan;102(1):96-105. (PMID: 11781072)
Biochem J. 2003 Nov 15;376(Pt 1):253-60. (PMID: 12911332)
Biochem Biophys Res Commun. 1998 Apr 17;245(2):319-24. (PMID: 9571148)
Biochem Biophys Res Commun. 2001 Aug 31;286(4):786-91. (PMID: 11520066)
J Immunol. 2005 Feb 1;174(3):1462-71. (PMID: 15661905)
J Interferon Cytokine Res. 2003 Jul;23(7):379-93. (PMID: 14511464)
J Immunol. 1994 Aug 1;153(3):1225-37. (PMID: 8027550)
Neuro Oncol. 2004 Apr;6(2):83-95. (PMID: 15134622)
J Immunother. 2003 Sep-Oct;26(5):385-93. (PMID: 12973027)
J Immunol. 1992 Mar 1;148(5):1404-10. (PMID: 1538124)
J Immunol. 2002 May 1;168(9):4772-80. (PMID: 11971028)
Biochem J. 1998 Aug 1;333 ( Pt 3):457-70. (PMID: 9677302)
Cancer. 2000 Aug 15;89(4):850-62. (PMID: 10951349)
Semin Cancer Biol. 2002 Feb;12(1):15-24. (PMID: 11926407)
Eur J Immunol. 1999 Mar;29(3):1032-40. (PMID: 10092108)
J Exp Med. 1999 Oct 4;190(7):1033-8. (PMID: 10510093)
J Immunol. 1990 Jun 1;144(11):4487-95. (PMID: 2160503)
J Natl Cancer Inst. 1996 Jan 17;88(2):100-8. (PMID: 8537970)
Oncogene. 2002 Aug 8;21(34):5213-23. (PMID: 12149643)
J Neuroimmunol. 1998 Dec 1;92(1-2):50-9. (PMID: 9916879)
Blood. 1991 Apr 1;77(7):1534-45. (PMID: 1706955)
Int J Oncol. 2003 Feb;22(2):431-7. (PMID: 12527945)
J Immunol. 1997 May 15;158(10):4521-4. (PMID: 9144461)
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2909-14. (PMID: 8610141)
معلومات مُعتمدة: F31 CA094834 United States CA NCI NIH HHS; NS-046463 United States NS NINDS NIH HHS; F31 CA94834 United States CA NCI NIH HHS; R21 NS056300 United States NS NINDS NIH HHS; R21 NS046463 United States NS NINDS NIH HHS; NS-056300 United States NS NINDS NIH HHS
المشرفين على المادة: 0 (Antineoplastic Agents, Alkylating)
0 (Cytokines)
0 (Fas Ligand Protein)
0 (HLA-A Antigens)
0 (Transforming Growth Factor beta)
0 (fas Receptor)
126547-89-5 (Intercellular Adhesion Molecule-1)
SY7Q814VUP (Calcium)
U68WG3173Y (Carmustine)
تواريخ الأحداث: Date Created: 20070407 Date Completed: 20070621 Latest Revision: 20181113
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC1894900
DOI: 10.1097/01.cji.0000211339.81211.25
PMID: 17414317
قاعدة البيانات: MEDLINE
الوصف
تدمد:1524-9557
DOI:10.1097/01.cji.0000211339.81211.25